5. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: A United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995;91:490-501. 6. Peeters P, Wlodarska I, Baens M, et al. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997;57:564-569. 7. Iwase S, Furukawa Y, Horiguchi-Yamada J, et al. A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome. Int J Hematol 1998;67:361-368. 8. van de Loosdrecht AA, Kok K, de Vries B, et al. Breakpoint analysis by fluorescence in situ hybridization in myelodysplastic syndromes with t(3;12)(q26;p13) and expression of EVI1. Leukemia 2000;14:1857-1858. 9. Nishimura Y, Wada H, Mori A, et al. Detection of ETV6/ MDS1/Evi-1 chimeric transcripts in a patient with acute myelo-cytic leukemia and t(3;12)(q26;p13). Int J Hematol 2000;72:108-109. 10. Massaad L, Prieur M, Leonard C, et al. Biclonal chromosome evolution of chronic myelomonocytic leukemia in a child. Cancer Genet Cytogenet 1990;44:131-137. 11. Mozziconacci MJ, Brunel V, Sainty D, et al. Translocation (3;12) (q26.2;p13.1) dans des hémopathies myéloïdes: Une nouvelle identité. Nouv Rev Fr Hématol 1995;37:124 (Abstract).